Showing 2 results for Rahmani
Dr Nawal Rahmani, Dr El-Houcine Sebbar, Dr Adnane Aarab, Dr Ali Azghar, Pr Mohammed Choukri,
Volume 2, Issue 2 (Summer-Fall 2019)
Abstract
In recent decades, new serum biomarkers have been developed for routine laboratory practice, such as assaying serum free light chains and more recently, assaying immunoglobulin heavy and light chain isotypes (Hevylite).
In this work, we highlight the interest of new biomarkers (Hevylite Test) in the management of monoclonal gammopathies because of the technical advantages it confers and the sensitive and unique clinical information that can be drawn from them.
Data from the latest studies show changes in the practice and use of Freelite and Hevylite tests in particular situations in the diagnosis and monitoring of MM, in situations where the monitoring of the tumor mass by conventional techniques is difficult. Freelite and Hevylite tests are proving to be of great benefit. The sFLC assay has already been recommended by international myeloma experts since 2009. There is no doubt that an integration of the Hevylite test for the diagnosis and monitoring of IgA MM will be done in the near future.
Dr Farhad Rahmanifar, Dr Nadiar Mussin, Dr Amin Tamadon,
Volume 6, Issue 2 (Summer-Fall 2023)
Abstract
Azoospermia, characterized by the absence of sperm in semen, poses a significant challenge to male fertility. Mesenchymal stromal/stem cell (MSC) therapy has emerged as a promising approach for treating azoospermia by promoting spermatogenesis and restoring fertility. MSCs possess the ability to differentiate into male germ cells and create a favorable microenvironment for spermatogenesis through the secretion of growth factors and cytokines. Preclinical studies have shown encouraging results, with improved testicular histology, sperm production, and fertility outcomes in animal models of azoospermia. Limited clinical studies in humans have also demonstrated the potential of MSC therapy in restoring spermatogenesis. However, challenges such as standardization of MSC isolation, characterization, and administration protocols, as well as the need for long-term safety and efficacy data, remain to be addressed. Despite these challenges, MSC therapy holds great promise for the treatment of azoospermia and warrants further research to optimize its use in clinical practice.
